works with clients to review existing coverage, for adequacy of current coverage, as well as any recommendations for additional coverage required for full protection.
ABIP is under development for the prevention of pulmonary fungal infections such as aspergillosis in high-risk immunosuppressed patients.
1) Using ABIP for patients at risk of developing the infection may potentially reduce the incidence of these infections, as well as associated high morbidity and mortality and significant treatment costs.
ABIP recently completed a multi-dose, dose escalation clinical study in preparation for pivotal trials to begin in 2007.
NOTE TO EDITORS: Information on ABIP data presented at major congresses by Nektar scientists is available by contacting Nektar Corporate Communications at 650-631-4954.